Angeleen Fleming, PhD, University of Cambridge, Cambridge, UK, discusses a recently developed technique for monitoring the clearance of aggregate-prone proteins within neurons in vivo. This technique can be used to assess genetic modifiers of disease, screen for and validate potential therapeutic agents and manipulate the proteasome. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).